Inovio Pharmaceuticals Inc (INO)
4.07
+0.01
(+0.25%)
USD |
NASDAQ |
Nov 22, 16:00
4.08
+0.01
(+0.25%)
Pre-Market: 20:00
Inovio Pharmaceuticals Cash from Financing (Quarterly): 0.6606M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.6606M |
| June 30, 2024 | 33.03M |
| March 31, 2024 | -11.36M |
| December 31, 2023 | 1.838M |
| September 30, 2023 | 0.6986M |
| June 30, 2023 | 2.883M |
| March 31, 2023 | -0.4247M |
| December 31, 2022 | 6.668M |
| September 30, 2022 | 3.812M |
| June 30, 2022 | 42.94M |
| March 31, 2022 | 28.42M |
| December 31, 2021 | 47.59M |
| September 30, 2021 | -0.4408M |
| June 30, 2021 | 3.441M |
| March 31, 2021 | 160.90M |
| December 31, 2020 | 126.94M |
| September 30, 2020 | -1.695M |
| June 30, 2020 | 126.52M |
| March 31, 2020 | 213.51M |
| December 31, 2019 | 9.645M |
| September 30, 2019 | 15.58M |
| June 30, 2019 | 1.294M |
| March 31, 2019 | 78.88M |
| December 31, 2018 | 14.39M |
| September 30, 2018 | 14.56M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.584M |
| March 31, 2018 | -0.5064M |
| December 31, 2017 | -0.1247M |
| September 30, 2017 | 70.89M |
| June 30, 2017 | 24.10M |
| March 31, 2017 | 0.8264M |
| December 31, 2016 | 0.8703M |
| September 30, 2016 | 4.369M |
| June 30, 2016 | 2.478M |
| March 31, 2016 | 0.0695M |
| December 31, 2015 | 0.1594M |
| September 30, 2015 | 1.727M |
| June 30, 2015 | 82.46M |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 1.167M |
| September 30, 2014 | 0.4987M |
| June 30, 2014 | 0.9051M |
| March 31, 2014 | 69.89M |
| December 31, 2013 | 4.522M |
| September 30, 2013 | 28.60M |
| June 30, 2013 | 0.0059M |
| March 31, 2013 | 19.56M |
| December 31, 2012 | 4.100M |
| September 30, 2012 | 1.226M |
| June 30, 2012 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.36M
Minimum
Mar 2024
213.51M
Maximum
Mar 2020
39.78M
Average
5.240M
Median
Cash from Financing (Quarterly) Benchmarks
| Novavax Inc | -0.097M |
| Baxter International Inc | -146.00M |
| AIM ImmunoTech Inc | 0.137M |
| Protalix BioTherapeutics Inc | -20.42M |
| Armata Pharmaceuticals Inc | -0.061M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.44M |
| Cash from Investing (Quarterly) | 14.08M |
| Free Cash Flow | -111.18M |
| Free Cash Flow Per Share (Quarterly) | -0.9752 |
| Free Cash Flow Yield | -107.8% |